{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T10:16:27Z","timestamp":1726481787393},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ijantimicag.2018.04.017","type":"journal-article","created":{"date-parts":[[2018,5,9]],"date-time":"2018-05-09T02:42:26Z","timestamp":1525833746000},"page":"350-357","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia"],"prefix":"10.1016","volume":"52","author":[{"given":"Ai Leng","family":"Khoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying Jiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen Lin","family":"Chee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Mei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siew Eng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang Piu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boon Peng","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Yang","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis Yi Ann","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0001","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0002","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0003","first-page":"720","article-title":"Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital","volume":"53","author":"Poon","year":"2012","journal-title":"Singapore Med J"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0004","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0025-7753(01)71921-5","article-title":"Comparative study of piperacillin\/tazobactam versus imipenem\/cilastatin in febrile neutropenia (1994\u20131996) [in Spanish]","volume":"116","author":"Figuera","year":"2001","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0005","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jjco\/hyq046","article-title":"Piperacillin\u2013tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital","volume":"40","author":"Oztoprak","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2005.05608.x","article-title":"Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial","volume":"130","author":"Reich","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0007","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1442-200X.2009.02952.x","article-title":"Imipenem\u2013cilastatin versus piperacillin\u2013tazobactam as monotherapy in febrile neutropenia","volume":"52","author":"Vural","year":"2010","journal-title":"Pediatr Int"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ctr.12685","article-title":"Piperacillin\u2013tazobactam vs. imipenem\u2013cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia","volume":"30","author":"Jing","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26360","article-title":"A prospective randomized trial comparing piperacillin\/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders","volume":"64","author":"Sano","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.ijantimicag.2018.04.017_bib0010","article-title":"Anti-pseudomonal \u03b2-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of \u03b2-lactams","author":"Paul","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0011","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.7314\/APJCP.2014.15.11.4549","article-title":"Meropenem versus piperacillin\u2013tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients","volume":"15","author":"Sezgin","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0012","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cmi.2017.03.024","article-title":"Comparison of antipseudomonal \u03b2-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis","volume":"23","author":"Horita","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0013","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0014","doi-asserted-by":"crossref","first-page":"287","DOI":"10.47102\/annals-acadmedsg.V41N7p287","article-title":"Prospective audit of post-chemotherapy febrile neutropenia in patients with solid cancer and lymphoma in two Singaporean cancer centres","volume":"41","author":"Wong","year":"2012","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0015","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0016","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1378\/chest.101.6.1481","article-title":"The ACCP-SCCM consensus conference on sepsis and organ failure","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0017","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0018","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0020","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JOP.091092","article-title":"How we treat febrile neutropenia in patients receiving cancer chemotherapy","volume":"6","author":"Lyman","year":"2010","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0022","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1086\/591531","article-title":"Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia\u2013myelodysplastic syndrome treated with intensive chemotherapy: an observational study","volume":"47","author":"Slobbe","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0023","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0024","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study\u2014Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0025","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0026","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/imj.12226","article-title":"Imipenem versus piperacillin\/tazobactam for empiric treatment of neutropenic fever in adults","volume":"43","author":"Roohullah","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0027","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/eji.201344404","article-title":"The potential impact of the pulmonary microbiome on immunopathogenesis of Aspergillus-related lung disease","volume":"44","author":"Kolwijck","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0028","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/21505594.2016.1257458","article-title":"The microbiome\u2013metabolome crosstalk in the pathogenesis of respiratory fungal diseases","volume":"8","author":"Gon\u00e7alves","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0029","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivoix","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.04.017_bib0030","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/imj.12596","article-title":"Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014","volume":"44","author":"Morrissey","year":"2014","journal-title":"Intern Med J"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T10:20:47Z","timestamp":1693650047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918301249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0924857918301249"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.04.017","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}